Enliven Therapeutics (NASDAQ:ELVN) Stock Price Down 5.6% – Here’s What Happened

by · The Cerbat Gem

Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) traded down 5.6% on Thursday . The stock traded as low as $26.58 and last traded at $26.63. 147,687 shares were traded during trading, a decline of 44% from the average session volume of 261,680 shares. The stock had previously closed at $28.21.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reiterated a “buy” rating and issued a $37.00 price target on shares of Enliven Therapeutics in a research note on Tuesday, October 1st.

Check Out Our Latest Analysis on Enliven Therapeutics

Enliven Therapeutics Price Performance

The firm’s 50 day simple moving average is $23.26 and its 200-day simple moving average is $22.15. The company has a market cap of $1.24 billion, a price-to-earnings ratio of -13.56 and a beta of 1.10.

Enliven Therapeutics (NASDAQ:ELVN – Get Free Report) last announced its earnings results on Tuesday, August 13th. The company reported ($0.41) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.17. On average, analysts forecast that Enliven Therapeutics, Inc. will post -1.98 EPS for the current year.

Insider Transactions at Enliven Therapeutics

In related news, insider Joseph P. Lyssikatos sold 12,000 shares of the stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $22.49, for a total transaction of $269,880.00. Following the completion of the sale, the insider now owns 1,077,936 shares in the company, valued at $24,242,780.64. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, CEO Samuel Kintz sold 2,270 shares of the business’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $27.56, for a total value of $62,561.20. Following the transaction, the chief executive officer now owns 1,061,255 shares of the company’s stock, valued at approximately $29,248,187.80. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Joseph P. Lyssikatos sold 12,000 shares of the firm’s stock in a transaction on Thursday, August 29th. The stock was sold at an average price of $22.49, for a total transaction of $269,880.00. Following the completion of the sale, the insider now owns 1,077,936 shares of the company’s stock, valued at $24,242,780.64. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 166,854 shares of company stock worth $4,255,626. Insiders own 29.20% of the company’s stock.

Institutional Investors Weigh In On Enliven Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of ELVN. Quest Partners LLC increased its position in shares of Enliven Therapeutics by 87.3% in the second quarter. Quest Partners LLC now owns 1,592 shares of the company’s stock valued at $37,000 after buying an additional 742 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in Enliven Therapeutics by 67.0% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 7,952 shares of the company’s stock valued at $140,000 after acquiring an additional 3,189 shares during the last quarter. American Century Companies Inc. increased its holdings in Enliven Therapeutics by 44.7% during the 2nd quarter. American Century Companies Inc. now owns 27,651 shares of the company’s stock valued at $646,000 after acquiring an additional 8,540 shares in the last quarter. EntryPoint Capital LLC acquired a new position in Enliven Therapeutics during the first quarter worth about $167,000. Finally, SG Americas Securities LLC purchased a new stake in shares of Enliven Therapeutics in the third quarter valued at about $256,000. Institutional investors and hedge funds own 95.08% of the company’s stock.

About Enliven Therapeutics

(Get Free Report)

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.

Featured Articles